Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

ROSEVILLE, Minn., April 14, 2026 (GLOBE NEWSWIRE)-- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today ...

Add Yahoo as a preferred source to see more of our stories on Google. Parade Pets and Yahoo may earn commission from links in this article. It's always fun to mix a few favorites and get a winning ...

It's always fun to mix a few favorites and get a winning combination. Think: chocolate and peanut butter. The beach and a good book. Or, even sweeter and more fun: a Golden Retriever and a Husky! In a ...

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

This is After Effects tutorial video to teach how to make Glitch effect. Apply to do a sort video that Cell (Dragon Ball) appears in tv to announces the Cell Games. Used: Fractal Noise and ...

You don’t need to be Willy Wonka or own a chocolate factory to make your own candy bars. It might sound intimidating, but chocolate bars are actually simple to make. Plus, doing it yourself gives you ...

It’s time to step out of the shadows, babe. Winter doesn’t have to mean another season buried in black sweaters and dark jeans. Let’s retire that outdated rule that says a fierce color combo is only ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Findings showed the trial met its primary endpoint demonstrating a statistically significant and clinically ...

Interim results from the phase 2 NESCIO trial suggest combination neoadjuvant immunotherapy has efficacy in locally advanced clear cell renal cell carcinoma. Neoadjuvant combinations of ipilimumab or ...